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The serine protease urokinase (uPA, urokinase-type plas-
minogen activator) is over-expressed in certain tumors
and is considered to be the strongest single indicator of
poor prognosis in patients with metastatic breast cancer.
In this article, we describe the isolation and affinity matu-
ration of a fully human recombinant antibody (termed
DS2), specific to the human uPA and capable of inhibit-
ing its enzymatic activity with an IC50 value in the low
nanomolar range. The novel antibody cross-reacts with
murine uPA. It was expressed both as scFv fragment and
in IgG format, allowing a systematic comparative immu-
nofluorescence (IF) analysis of the uPA expression pat-
terns in a large panel of human und murine tumors and
of normal human tissues. Although uPA was strongly
expressed in virtually all tumor specimens tested, it exhib-
ited only a weak expression in certain normal tissues
(mainly in the colon, lung, spleen and bone marrow).
IgG(DS2) was not able to inhibit cancer growth in immu-
nocompromised mice bearing subcutaneous human
MDA-MB-231 or DoHH-2 tumors. However, an ex vivo
IF analysis confirmed the ability of the DS2 antibody to
preferentially localize at the tumor site compared with
normal organs. Collectively, these data suggest that uPA
blocking antibodies may not be indicated for cancer
growth inhibition strategies, but may serve as valuable
tools for the implementation of pharmacodelivery strat-
egies against a variety of different tumors.
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Introduction
The use of monoclonal antibodies in cancer therapy con-
tinues to gain in importance, due to the ability of these mol-
ecules to concentrate therapeutic effects onto neoplastic
lesions while sparing normal organs (Carter, 2006; Schrama
et al., 2006; Weiner, 2006). Although originally monoclonal
antibodies specific to membrane antigens on cancer cells
have been used for tumor targeting applications, alternative
targets such as markers of angiogenesis (Neri and Bicknell,
2005), stromal antigens (Hofheinz et al., 2003; Schliemann
and Neri, 2007; Rybak et al., 2007) and intracellular proteins
released at sites of necrosis (Miller et al., 1993; Street et al.,
2006) are increasingly being considered. In this context, we
and others have shown that the antibody-based targeting of
enzymes, which are up-regulated at the tumor site, may rep-
resent an additional attractive avenue for therapeutic appli-
cations (Chrastina et al., 2003; Ahlskog et al., 2009a,b;
Pfaffen et al., 2009).
The urokinase-type plasminogen activator (uPA) is a
trypsin-like serine protease that can activate plasminogen
into catalytically active plasmin. uPA exhibits only 54%
similarity in amino acid sequence with the second endogen-
ous plasminogen activator tPA (tissue-type plasminogen acti-
vator). While the main biological function of tPA seems to
be associated with fibrinolysis, uPA is a central molecule in
pericellular proteolysis and remodeling of the extracellular
matrix (ECM; Carriero et al., 2009). uPA is produced as a
single-chain pro-uPA that binds to a specific receptor
(uPAR) on the surface of tumor and stromal cells. Upon
binding to uPAR, pro-uPAR is converted to enzymatically
active uPA mainly by plasmin. Active uPA in turn catalyzes
plasminogen activation. Plasmin then activates a series of
other proteases such as matrix metalloproteinases (MMPs),
thereby triggering remodeling and degradation of the ECM.
uPA can also activate the precursor to the hepatocyte
growth factor pro-HGF, which shows extensive homology
with plasminogen, and the macrophage stimulating protein,
thereby indirectly controlling cell proliferation, ECM inva-
sion and prevention from apoptosis (van der Voort et al.,
2000; Collen, 2001). Two endogenous uPA inhibitors, PAI-1
and PAI-2 (plasminogen inhibitor type 1 and 2), are known
to inhibit the enzyme. PAI-1 forms covalent complexes with
uPA that are rapidly cleared by uPAR-dependent internaliz-
ation, if the protease is receptor bound (Cubellis et al., 1990;
Olson et al., 1992).
Several studies have established that uPA levels are elev-
ated in certain tumors (Duffy, 1996; Sier et al., 1998).
Importantly, high levels of uPA in extracts of primary breast
carcinomas were reported to predict early relapse and poor
prognosis (Duffy et al., 1998). This relationship was later
confirmed with other cancer types (Duffy and Duggan,
2004). In the clinic, the two proteins such as uPA and PAI-1
are considered to be the strongest known prognostic indi-
cators of shortened disease-free survival and overall survival
in breast cancer and the most accurate predictors of metasta-
sis in lymph-node negative tumors (Look et al., 2002; Lee
et al., 2004). These data suggest that uPA may play a func-
tional role in breast cancer progression, but the experimental
evidence is still controversial. Experiments with cell cultures
and animal models have indicated a biological role of
uPA-catalyzed plasminogen activation in tumor progression
(Dano et al., 1985; Andreasen et al., 1997). Studies
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indicating decreased metastatic load in uPA-deficient mice
(uPA2/2 mice) support the idea that uPA activity contributes
to local invasion and metastasis. However, primary lesions
could still grow in the absence of this enzyme (Almholt
et al., 2005).
The inhibition of the proteolytic activity of uPA for thera-
peutic purposes has so far mainly been addressed with small
organic compounds. A number of low-molecular-weight uPA
inhibitors are currently in clinical development, based on the
observation of a reduced metastatic load in mouse models of
breast cancer (Ke et al., 1997; Tamura et al., 2000;
Schweinitz et al., 2004). Only a few polyclonal and mono-
clonal antibodies generated in mouse and rabbit have been
described so far (Ossowski and Reich, 1983; Salerno et al.,
1984; Petersen et al., 2001), but to our knowledge their per-
formance in tumor inhibition or in pharmacodelivery exper-
iments has not yet been reported. Furthermore, human
monoclonal antibodies would be needed for applications in
humans.
Antibody phage display technology has revolutionized the
way human monoclonal antibodies are isolated (Winter
et al., 1994). Typically, single-pot phage display libraries
containing billions of different antibody clones are panned
on a target antigen, immobilized on a suitable support, yield-
ing good-quality binding specificities which can be used for
a variety of applications (e.g. ELISA, immunoblotting,
immunohistochemistry etc.; Nissim et al., 1994; Silacci
et al., 2005). If appropriate, phage antibodies can be affinity
matured by combinatorial mutagenesis and by panning the
resulting libraries under stringent conditions (Winter et al.,
1994; Pini et al., 1998; Silacci et al., 2006; Villa et al.,
2008). Our laboratory has previously developed and validated
large antibody phage display libraries, from which specific
antibodies in scFv format can be isolated against a variety of
different antigens (Pini et al., 1998; Silacci et al., 2005;
Pfaffen et al., 2009). Additionally, many groups (including
ours) have implemented technologies for the efficient con-
version of scFv fragments into the full human IgG format
(Zuberbuhler et al., 2009). Indeed, intact immunoglobulins
may be a preferable format, due to their long circulatory
half-life and to their ability to engage Fcg receptors and acti-
vate the complement system.
Here, we describe the isolation, affinity maturation and
characterization of a potent inhibitory human monoclonal
antibody, specific to uPA. A comprehensive immunofluores-
cence (IF) analysis in healthy and cancer tissues revealed
that uPA is strongly expressed in the majority of tumors
tested, while being undetectable or only moderately
expressed in normal tissues. The anti-uPA antibody was not
able to inhibit tumor growth in mouse models, but exhibited
an ability to preferentially localize at the tumor site follow-
ing intravenous administration, thus making it a suitable can-
didate for antibody-based pharmacodelivery strategies.
Materials and methods
Cell lines
Cell culture media and supplements were purchased from
Invitrogen (Basel, Switzerland).
The human glioblastoma cell line U87 (HTB-14, ATCC)
was cultured in MEM medium, supplemented with 10% fetal
calf serum (FCS) and antibiotic–antimycotic at 378C and
5% CO2. The murine teratocarcinoma cell line F9
(CRL-1720, ATCC) and the human breast adenocarcinoma
cell line MDA-MB-231 (HTB-26D, ATCC) were cultured in
DMEM containing 10% FCS and incubated at 378C and 5%
CO2. The human ovarian cancer cell line SKOV-3 (HTB-77,
ATCC) and the murine colon carcinoma cell line colon-38
were cultured in RPMI 1640 supplemented as described
above. The human follicular lymphoma cell line DoHH-2
(DSMZ; Braunschweig, Germany) was maintained in log-
phase growth in RPMI 1640 medium adjusted to contain
2 mM L-glutamine, 10 mM N-2-hydroxyethylpiperazine-N0-2-
ethanesulfonic acid (HEPES), 1 mM sodium pyruvate,
4.5 g l21 glucose, 1.5 g l21 bicarbonate, 10% FCS and anti-
biotic–antimycotic at 378C and 5% CO2.
Selection of antibodies from the ETH-2-Gold library
by phage display
Human monoclonal antibodies specific to uPA were isolated
by biopanning from the ETH-2-Gold antibody phage display
library (Silacci et al., 2005). Antibody selections were
carried out on Immunotubes (Nunc, Roskilde, Denmark)
coated with uPA (Accurate Chemicals, Westbury, NY, USA)
at 54 mg ml21 in PBS (20 mM NaH2PO4, 30 mM Na2HPO4,
100 mM NaCl, pH 7.4), as described previously (Silacci
et al., 2005).
Bacterial supernatants containing recombinant antibody
fragments were screened by ELISA as described previously
(Viti et al., 2000). Clones with positive signal in ELISA
were expressed in E.coli TG-1 and purified from culture
supernatant by affinity chromatography using Protein A
Sepharose Fast Flow resin (GE Healthcare, Otelfingen,
Switzerland), as described previously (Silacci et al., 2005).
Purified scFv format antibodies were analyzed by surface
plasmon resonance (SPR) real-time interaction analysis on a
high-density coated antigen-chip, using a BIAcore 3000
instrument (BIAcore AB, GE Healthcare).
Sequencing of scFv antibody genes
Antibodies were sequenced using Big Dyew Terminator V
3.1 Cycle Sequencing kit (Applied Biosystems, Foster City,
CA, USA) on an ABI PRISM 3130 Genetic analyzer.
Termination reactions were performed using primers
Limb3long 50-CAG GAA ACA GCT ATG ACC ATG ATT
AC-30 (annealing 110 bp upstream the scFv gene) and fdseq-
long 50-GAC GTT AGT AAA TGA ATT TTC TGT ATG
AGG-30 (annealing 100 bp downstream the scFv gene;
Eurofins MWG Operon, Ebersberg, Germany).
Characterization of scFv antibody fragments
ScFv antibody fragments were expressed in E.coli and puri-
fied from culture supernatant by affinity chromatography
using Protein A Sepharose Fast Flow Resin (GE Healthcare),
as described previously (Silacci et al., 2005).
Purified antibodies were analyzed by SDS–PAGE and
size exclusion chromatography on a Superdex 75 HR10/30
column (Amersham Biosciences, GE Healthcare), and the
peak of the monomeric fraction was collected and used for
affinity measurement by BIAcore on a low-density coated
antigen chip.
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Construction of affinity maturation libraries
Affinity maturation libraries were constructed by introducing
sequence variability either in the CDR1 loops of heavy
(VH) and light chain (VL) or in the CDR2 loops of VH
and VL. Antibody residues are numbered according to
Tomlinson et al. (1992). Mutations at positions 31, 31a, 32
(CDR1 of VL) and 31, 32, 33 (CDR1 of VH) or 50, 51, 52
(CDR2 of VL) and 52, 52a, 53 and 56 were introduced by
PCR using partially degenerate primers (Eurofins MWG
Operon) as described previously (Silacci et al., 2006; Villa
et al., 2008).
Phage display selections were carried out as described
above. Briefly, one single round of panning was performed
on uPA immobilized on immunotubes (Nunc) at 1027 M
concentration which corresponds to a 10-fold reduced con-
centration compared with the initial selections. Bound phage
was eluted with 100 mM triethylamine, as described in
Silacci et al. (2005). Induced supernatants of individual
clones were screened by ELISA and ranked by SPR analysis
on a high-density coated antigen chip. The selections yielded
the scFv format antibody DS2.
Cloning and expression of IgG(DS2)
The heavy and light chain of the human IgG1 format of
DS2 were cloned as described in Zuberbuhler et al. (2009).
Equimolar amounts of the recombinant vectors were used to
cotransfect CHO-S cells (Gibco/Invitrogen, Basel,
Switzerland) using Amaxa Nucleofactor (Amaxa AG,
Cologne, Germany) following the manufacturer’s protocol.
Transfectomas were selected using 500 mg ml21 of
Geneticin (G418, Calbiochem, San Diego, CA, USA) and
250 mg ml21 hygromycin B (Invitrogen). After 14 days of
selection in RPMI medium supplemented with 10% FCS
and selective antibiotics, cells were brought into suspension,
and cultured in PowerCHO-CD 2 medium (Lonza, Vervier,
Belgium).
Staining of recombinant CHO-S for secreted product and
fluorescent-activated cell sorting FACS were performed as
described earlier (Zuberbuhler et al., 2009). IgG(DS2) was
purified from cell culture medium of monoclonal line by
protein A affinity chromatography. The purified protein was
analyzed by SDS–PAGE and size exclusion chromatography
using a Superdex 200 HR 10/30 column.
Surface plasmon resonance (BIAcore)
Affinity measurements were performed on a BIAcore 3000
instrument. Antigen-coated chips were prepared by coupling
antigen covalently to a CM5 sensor chip (BIAcore). For a
high-density chip, low-density chip and ultra-low-density
chip, 1000 RU of uPA, 300 RU and 100 RU, respectively,
were immobilized per flow cell.
For the determination of the dissociation constants, the
monomeric fraction of scFv(DS2) was collected by
size-exclusion chromatography as described above. Serial
2-fold dilutions of the monomer were then used for real-time
interaction analysis on the low-density chip at a flow rate of
20 ml min21. The kinetic constants kon, koff and KD were
evaluated using the BIAevaluation 4.1 software (BIAcore).
In addition, the KD value of the scFv(DS2) was determined
by plotting the RU values at saturation against the concen-
tration of the scFv antibody and fitting with the equation
below:
RU ¼ RUmax
1 þ KD=c½scFv ð1Þ
The apparent affinity of the IgG(DS2) was analyzed on an
ultra-low-density chip using the BIAevaluation 4.1 software.
uPA inhibition assay
The inhibitory potentials of scFv(DS2) and IgG(DS2) were
analyzed in a uPA inhibition assay as described by
Scheuermann et al. (2008). Briefly, uPA (Accurate
Chemicals) at 18.5 nM concentration was incubated with
varying concentrations of the antibodies DS2 in 96-well
microtiter plates (Nunc) for 15 min at room temperature. The
reaction was started by addition of the fluorogenic substrate
Z-RRG-AMC (Bachem, Bubendorf, Switzerland) dissolved
in PBS to a final concentration of 0.1 mM in a total volume
of 100 ml. The change in fluorescence signal (lex: 383 nm;
lem: 455 nm; cutoff filter: 420 nm) was recorded over 10
min using a SpectraMax microplate reader (Molecular
Devices, Sunnyvale, CA, USA). The rate of fluorescence
signal increase over time (dRFU/dt ¼ reaction velocity v)
was plotted against the corresponding inhibitor concen-
trations, and the IC50 value for the inhibitor was obtained by
fitting to the equation below (KaleidaGraph V 4.0, Synergy
Software):
v ¼ a 0:5  ðI0  E0 þ IC50 þ ððI0  E0 þ IC50Þ2
þ 4  IC50  E0Þ0:5Þ ð2Þ
where [I]0 is initial inhibitor concentration and [E]0 is
enzyme concentration.
IF on frozen tissue sections
Tumor tissue was embedded in cryoembedding medium
(Microm, Volketswil, Switzerland), snap frozen in liquid
nitrogen and stored at 2808C until sectioned. Tissue sections
(10 mm) were fixed for 1 h in 4% paraformaldehyde (PFA),
blocked with FCS and then stained for uPA. The IgG(DS2)
was applied at 10 mg ml21 and detected with goat anti-
human IgG antibody (Sigma-Aldrich, St. Louis, MO, USA),
followed by donkey anti-goat Alexa Fluor 594 antibody
(Invitrogen). Nuclei were counterstained with 1 mg ml21
DAPI (40,6-diamidino-2-phenylindole; Invitrogen). All com-
mercial reagents were diluted according to manufacturer’s
recommendation. Rinsing with PBS was performed in
between all incubation steps. Finally, slides were mounted
with Glycergel mounting medium (Dako, Glostrup,
Denmark) and analyzed with a Zeiss Axioskop 2 mot fluor-
escence microscope (Carl Zeiss AG, Feldbach, Switzerland).
Images were captured with an AxioCam MRC using
AxioVision 4.7 image analysis software (Carl Zeiss AG).
The cross-reactivity of IgG(DS2) with normal tissue was
studied on an FDA standard panel of healthy tissue
(Biochain, Hayward, CA, USA). Sections were blocked with
FCS and then incubated with 10 mg ml21 of purified
FITC-labeled IgG(DS2) for 1 h. For signal amplification,
bound antibody was detected using rabbit anti-FITC antibody
(MorphoSys, Oxford, UK) followed by Alexa Fluor 594 goat
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anti-rabbit IgG (Invitrogen). Slides were analyzed as
described above.
Immunocytochemistry/confocal laser scanning microscopy
Confocal laser scanning microscopy was done on formalin-
fixed F9 cells grown on 4.2 cm2 Falcon cell culture inserts (BD
Biosciences, Allschwil, Switzerland) using the IgG(DS2) at
10 mg ml21. Binding was detected with a goat anti-human IgG
antibody (Sigma-Aldrich), followed by donkey anti-goat Alexa
Fluor 594 (Invitrogen). Nuclei were counterstained with
1 mg ml21 DAPI. Slices were mounted with mounting medium
(70% (v/v) glycerol, 30 mmol l21 Tris–HCl (pH 9.5), 5%
(w/v) n-propyl-gallate (Sigma)) and analyzed with an LSM
510 META from Zeiss. Images were further processed using
the IMARIS software (Bitplane AG, Zurich, Switzerland).
Tumor studies in mice. DoHH-2 lymphoma cells (1  107)
were injected subcutaneously into the flank of 6- to
8-week-old female CB17/lcr SCID mice. MDA-MB-231
human breast carcinoma cells (2  106) were injected into
the flank of 6- to 8-week-old female BALB/c nude mice.
When tumors were established and clearly palpable (50–
100 mm3), mice were staged to maximize uniformity among
the groups and injected into the lateral tail vein with either
200 mg IgG(DS2) (corresponding to a dosage of 10 mg anti-
body per kg of body weight), 200 mg human IgG isotype
control (Cell Sciences, Canton, MA, USA), or control saline
in a volume of 200 ml. All agents were injected weekly.
Mice were monitored daily, and tumor growth was
measured three times per week with a digital caliper using the
following formula: volume ¼ length  width2  0.5. Animals
were killed when the tumor reached a volume of .2000 mm3.
All in vivo experiments were carried out according to
Swiss regulations under a project license granted by the
Veterina¨ramt des Kantons Zu¨rich (169/2008).
Ex vivo fluorescence experiments. Two hundred micrograms
of IgG(DS2) or an isotype control IgG antibody were injected
intravenously into the lateral tail vein of mice bearing subcu-
taneously implanted murine F9 teratocarcinomas or human
DoHH-2 follicular lymphomas. Animals were sacrificed 18 h
after injection and tumors and normal organs (i.e. the heart,
kidney, liver and lung) were excised, embedded in cryoem-
bedding compound (Microm) and stored at 2808C. Sections
(10 mm) were cut and fixed with 4% PFA. For detection of
injected IgG, goat anti-human IgG (Sigma-Aldrich) was
applied, followed by donkey anti-goat Alexa Fluor 594
(Invitrogen). Endothelial cells were stained ex vivo with a rat
anti-mouse CD31 antibody (BD Pharmingen, San Jose, CA,
USA). Alexa Fluor 488 rabbit anti-rat IgG (Invitrogen) served
as secondary antibody. Nuclei were counterstained with
1 mg ml21 DAPI (Invitrogen). All commercial reagents were
diluted according to manufacturer’s recommendation. Rinsing
with PBS was performed in between all incubation steps.
Slides were analyzed as described above.
Results
Antibody phage display selections against uPA
The human uPA was used for the isolation of human mono-
clonal antibodies from the ETH-2-Gold phage antibody
library (Silacci et al., 2005). Clones from this library feature
diversity in the CDR3 loops of the VH and VL domain. The
library contains a single VH germline gene (DP47, which
confers binding to Protein A (Hoogenboom and Winter,
1992)), while the VL domain is based either on a Vk
DPK-22 scaffold (Tomlinson et al., 1992) or on a Vl
DPL-16 scaffold (Tomlinson et al., 1992). Monoclonal anti-
bodies in scFv format were isolated from the library by bio-
panning on immobilized antigen (Silacci et al., 2005) and
showed specific binding in ELISA and SPR analyses.
Selected clones were affinity matured by combinatorial muta-
genesis of residues in the CDR1 and CDR2 loops of VH and
VL domains, according to a procedure previously described
by our group (Villa et al., 2008). This methodology yielded
the human monoclonal antibody DS2 (Fig. 1), specific to
human uPA and capable of cross-reacting with murine uPA
(83% identity between the two proteins).
DS2 was expressed as scFv fragment in E.coli and purified
from culture supernatant by protein A affinity chromato-
graphy, according to standard procedures (Silacci et al.,
2005). In addition, the antibody was cloned and expressed as
full human IgG (Zuberbuhler et al., 2009). The IgG was pro-
duced in CHO-S cells and purified from cell culture medium
by protein A affinity chromatography, with non-optimized
yields of 20 mg antibody per liter of culture from roller
bottles. Both scFv and IgG antibody preparations were ana-
lyzed by SDS–PAGE and gel filtration (Fig. 2).
In vitro characterization of scFv(DS2) and IgG(DS2)
The dissociation constant of scFv(DS2) to human uPA was
determined by BIAcore technology on a low-density micro-
sensor chip, using the monomeric fraction of the scFv frag-
ment isolated by size-exclusion chromatography. Figure 3a
illustrates the BIAcore sensograms of scFv(DS2), which
revealed a dissociation constant KD of 6.4 nM [kon ¼ 2.5 
105 M21 s21 and koff ¼ 1.5  1023 s21]. This value is in line
with the KD value (¼7.1 nM) obtained from the fitting of
Fig. 1. ScFv antibody fragment structure, and relevant amino acid positions
of the DS2 antibody. Positions that are mutated in the primary antibody
library (ETH2-Gold) are underlined. Residues mutated during the affinity
maturation process are in boldface. Single amino acid codes are used
according to standard IUPAC nomenclature. aNumbering according to
Tomlinson et al. (1992).
D.Sgier et al.
264
RU values at saturation against the scFv concentration
(Fig. 3b).
Both scFv(DS2) and IgG(DS2) exhibited good selectivity
for uPA over other trypsin-like enzymes as thrombin, Factor
Xa, trypsin, chymotrypsin B, tPA and plasmin (Fig. 4). The
antibodies recognized both the catalytically active two-chain
uPA and the single-chain pro-uPA precursor.
Enzymatic inhibition
Both scFv(DS2) and IgG(DS2) were characterized in terms
of their IC50 values for the inhibition of human uPA proteo-
lytic activity. For scFv(DS2), an IC50 value of 6.7 nM was
found. IgG(DS2) exhibited an IC50 value of 8.9 nM (Fig. 5).
Both IC50 values are in line with the KD values determined
by BIAcore analysis.
IF analysis with IgG(DS2)
The recombinant antibody IgG(DS2) was extensively charac-
terized by IF on cryosections of murine and human (xeno-
graft) tumors and on healthy human tissues. In all tumors
studied (human breast adenocarcinoma MDA-MB-231,
human ovarian carcinoma SKOV-3, human B-cell lymphoma
DoHH-2, human glioblastoma U87, murine F9 teratocarci-
noma and murine colon-38 adenocarcinoma), a moderate to
very strong staining could be observed. The strongest stain-
ings were seen on MDA-MB-231 breast cancer, SKOV-3
Fig. 2. Protein purification. SDS–PAGE analysis of the purified (a) scFv(DS2) and (c) IgG(DS2) under non-reducing (nr) and reducing (r) conditions.
Size-exclusion chromatography of the purified (b) scFv(DS2) and (d) IgG(DS2) is also shown.
Fig. 3. BIAcore analysis of the purified monomeric scFv(DS2). The scFv antibody revealed a dissociation constant KD of 6.4 nM (a). In addition, the affinity
of scFv(DS2) was analyzed by plotting RU values at saturation against the different antibody concentrations (b). KD value fitting with the KaleidaGraph V 4.0,
Synergy Software revealed a KD of 7.1 nM.
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ovarian carcinoma and F9 teratocarcinoma (Fig. 6a). The
staining performance of IgG(DS2) at the subcellular level
was characterized by confocal laser scanning microscopic
analysis on F9 cells, revealing expression in the cytoplasm
and on the cell membrane (Fig. 6b).
The patterns of uPA expression in normal human tissue
were studied on a FDA standard panel of health tissues
(three donors per organ) using a frozen tissue array. uPA was
undetectable in most tissues, while a moderate straining was
observed in normal colon, lung, spleen, bone marrow and
stomach (in one-thirds of donors only; Supplementary
Figure S1 available at PEDS online).
Therapeutic activity of IgG(DS2) against localized
tumor growth
To evaluate the therapeutic activity of IgG(DS2) in terms of
primary tumor growth inhibition, mice bearing a subcu-
taneous MDA-MB-231 human breast adenocarcinoma or an
F9 murine teratocarcinoma were treated with weekly injec-
tions of either IgG(DS2) (200 mg), isotype control IgG or
saline. No inhibition of primary tumor growth was observed
(Fig. 7).
In vivo tumor targeting performance of IgG(DS2)
Mice bearing subcutaneous F9 or DoHH-2 tumors were
injected intravenously with 200 mg of IgG(DS2) or of an
isotype-matched monoclonal human antibody of irrelevant
specificity in the experimental setting. After 18 h, mice were
sacrificed and freshly frozen sections of tumors and healthy
Fig. 4. Characterization of the inhibitory potential of the antibody DS2. The
enzymatic activity of urokinase was measured in the presence of the
antibodies scFv(DS2) and IgG(DS2) in varying concentrations. The reaction
velocity, v, was plotted against the corresponding inhibitor concentrations,
and the IC50 values of inhibitors were fitting with the KaleidaGraph V 4.0,
Synergy Software.
Fig. 5. Specificity of the uPA-binding antibodies. ELISA signals against
other trypsin-like serine proteases. No antigen: wells only blocked with PBS,
milk.
Fig. 6. Immunofluorescence analysis. IF performed on cryosections of
murine and human (xenograft) tumors (a) (human breast adenocarcinoma
MDA-MB-231, human ovarian carcinoma SKOV-3, human B-cell
lymphoma Do-HH-2, human glioblastoma U87, murine F9 teratocarcinoma
and murine colon-38 adenocarcinoma) (b). Characterization of subcellular
expression of uPA in murine F9 teratocarcinoma cells. uPA was stained in
red, whereas cell nuclei were stained in blue using DAPI. Scale bars
represent 50 mm.
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organs were stained for human IgG (red), blood vessels
(CD31 staining; green) and nuclei (DAPI staining; blue). A
preferential uptake of IgG(DS2) in both tumors was
observed. A weak staining of the liver for both specific and
isotype-control antibodies could also be observed, compati-
ble with liver recycling and hepatobiliary clearance of IgG
molecules (Fig. 8). At these concentrations, IgG(DS2)
reached structures distant from the tumor vasculature in both
cancers. However, while the staining of tumor cells was
homogenous in the DoHH-2 model, a heterogenous pattern
of antibody uptake was observed for F9 tumors, in line with
the ex vivo analysis of tumor sections (see also Fig. 6).
Discussion
In this article, we have described the isolation and affinity
maturation of a human recombinant antibody against the
serine protease uPA. The monoclonal antibody DS2 (in scFv
and in IgG format) binds uPA with high affinity in the low
nanomolar range without cross-reactivity to other serine
proteases.
Urokinase activates plasminogen by cleavage of the
Arg561–Val562 bond in the catalytic domain of the zymogen
(Andreasen et al., 2000). Our antibodies scFv(DS2) and
IgG(DS2) were evaluated regarding their inhibitory potential
in an in vitro enzyme assay using a synthetic fluorogenic
peptide Z-Gly-Gly-Arg-AMC. Results with this assay were
shown to correlate with those of the standard plasminogen
activation assay (Zimmerman et al., 1978; Pierzchala et al.,
1979). The antibodies DS2 exhibited IC50 values in the nano-
molar range that closely matched the corresponding KD value.
uPA has been implicated in tumor invasion and metastasis
formation (Kim et al., 1998). Upregulation of uPA and its
receptor in tumor tissue often correlates with increased
malignancy and poor prognosis for patients with breast
cancer and several other malignant tumors (Schmitt et al.,
1997; Harbeck et al., 2002; Reuning et al., 2003). At present,
only a few potent and selective uPA inhibitors have been
developed, which could be used in animal models to evaluate
the influence of the proteolytic activity of uPA on cancer
metastasis and invasion (Tyndall et al., 2008; reviewed in
Carriero et al., 2009).
It is recognized that membrane localization of uPA by
interaction with the uPAR is of relevance to the enzymatic
activity of uPA. In particular, kinetic studies have shown
that receptor-bound uPA exhibits a considerably increased
catalytic efficiency compared with the soluble protein (Ellis
et al., 1991; Ploug et al., 2002). By SPR experiments with
the uPAR (adapted from Kim et al., 2003), we could show
that the antibody DS2 binds equally to soluble and
receptor-bound uPA (data not shown) and does not influ-
ence the uPA–uPAR interaction. These observations are in
line with the fact that IgG(DS2) targets tumor cells in vivo
(Fig. 8).
When exploring the patterns of antigen expression in
health and in cancer, it is important to consider data from the
Fig. 7. Therapeutic activity of IgG(DS2) against primary tumor growth. Immunodeficient mice bearing subcutaneous MDA-MB-231 human breast
adenocarcinomas (a) or DoHH-2 human follicular lymphomas (b) were treated with weekly injections (200 mg) of IgG(DS2) (filled square), human IgG
isotype control (filled triangle) or saline (cross marks). Data represent mean tumor volumes (+SE).
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Human Protein Atlas (Berglund et al., 2008), a useful
resource which compiles immunohistochemical data from
commercial and custom-derived monoclonal and polyclonal
antibodies. For these comparisons, it is important to consider
that monoclonal antibodies of different affinity and epitope
may sometimes yield contrasting staining results (Pfaffen
et al., 2009). In our hands, the DS2 antibody exhibited a
stronger staining of tumors compared with the data presented
in the Human Protein Atlas. As for normal tissues, there was
a general agreement, but we observed a moderate staining of
certain normal tissues (e.g. lung, spleen and bone marrow),
which had not previously been reported.
For many years, the research of our group has focused on
the identification and validation of monoclonal antibodies
with a pan-tumoral coverage potential. Even though certain
markers of the sub-endothelial ECM (e.g. splice isoforms of
tenascin-C, fibronectin and periostin) show a more restricted
pattern of expression in normal tissues compared with DS2,
the results presented in this article are still compatible with a
possible role of anti-uPA antibodies for pharmacodelivery
strategies (Carnemolla et al., 1996; Pini et al., 1998; Tarli
et al., 1999; Viti et al., 1999; Borsi et al., 2002; Castellani
et al., 2002; Neri and Bicknell, 2005; Berndorff et al., 2006;
Brack et al., 2006; Tijink et al., 2006, Villa et al., 2008;
Ahlskog et al., 2009a,b; Pedretti et al., 2009; Pfaffen et al.,
2009; Schliemann et al., 2009a,b; Schwager et al., 2009).
There is growing evidence that tumor-targeting monoclonal
antibody derivatives (e.g. immunocytokines, radiolabeled
antibodies, drug conjugates) may display tumor eradication
potential both in animal models of cancer and in patients
(Sauer et al., 2009; Schliemann et al., 2009a,b).
When injected at high doses, IgG(DS2) exhibited an
impressive potential to homogenously reach tumor cells
in vivo, including those not adjacent to vascular structures.
Other reports from our group have shown that tumor antigens
located hundreds of micrometers from the nearest blood
vessels (e.g. carbonic anhydrase IX expressed at sites of
hypoxia) can be targeted in vivo by cognate monoclonal anti-
bodies (Ahlskog et al., 2009b). This contrasts with a previous
study on the intravenous administration of Herceptin at high
doses (10 mg/kg) in mice bearing F2-1282 tumors (Dennis
et al., 2007), which evidenced a pattern of antibody uptake
restricted to perivascular tumor cells. There is increasing evi-
dence that antibody format, affinity, dose, patterns of antigen
expression and vascular permeability of the individual tumor
models may all contribute to the efficiency of in vivo anti-
body localization (Begent, 1999; Boerman et al., 2003;
Adams et al., 2006; Ahlskog et al., 2009a; Schmidt and
Wittrup, 2009).
To the best of our knowledge, most preclinical and clini-
cal reports on pharmaceutical uPA inhibition strategies are
based on low-molecular-weight inhibitors. High-affinity uPA
blockers have been reported (Schweinitz et al., 2004), which
allowed reduction of metastatic spread in animal models of
tumor metastasis. Reduction of primary tumor growth was
not reported so far. Additionally, off-target effects (i.e.
undesired inhibition of other proteases or of other target
proteins) may complicate the interpretation of preclinical
therapy data.
In principle, monoclonal antibodies should represent the
most selective avenue for validating the pharmaceutical
potential of a putative tumor target. Impressive results on the
inhibition of metastatic spread have been reported with uPA
blockers (Schweinitz et al., 2004), which are in line with
genetic data obtained in uPA2/2 tumor-bearing mice
(Almholt et al., 2005). In this article, we report that the
potent uPA blocking antibody IgG(DS2) was not capable of
inhibiting the growth of uPA-positive primary tumors. It is
possible that the DS2 antibody may exhibit a therapeutic
effect in preventing metastatic spread in animal models.
However, in the clinical setting, patients often present with
established bulky metastases and it is not clear whether the
inhibition of new micrometastases may justify the develop-
ment of a new pharmaceutical agent, to be combined with
other regimens. The data presented in this article suggest a
main role of uPA as a tumor-associated antigen for pharma-
codelivery applications, rather than for the inhibition of pro-
teolytic activity or for Fc-mediated anti-cancer strategies.
Fig. 8. In vivo localization experiments: ex vivo immunofluorescence. Mice bearing subcutaneous F9 murine teratocarcinomas (a) or DoHH-2 human follicular
lymphomas (b) were injected with 200 mg of IgG(DS2) or isotype-matched control IgG. The figure shows microscopic images of tumor and organ sections
18 h after injection, confirming localization of IgG(DS2) at the site of tumor (red, injected IgG; green, ex vivo fluorescence staining of CD31; blue, nuclei).
Scale bars represent 50 mm.
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